WINTON GROUP Ltd Trims Stake in Boston Scientific Co. (NYSE:BSX)

WINTON GROUP Ltd lessened its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 8.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 56,146 shares of the medical equipment provider's stock after selling 5,240 shares during the quarter. WINTON GROUP Ltd's holdings in Boston Scientific were worth $5,015,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Mechanics Bank Trust Department bought a new stake in shares of Boston Scientific in the fourth quarter valued at $415,000. Highland Capital Management LLC purchased a new stake in Boston Scientific in the 4th quarter worth about $4,887,000. Covenant Asset Management LLC bought a new stake in Boston Scientific in the 4th quarter valued at about $3,405,000. Brookstone Capital Management boosted its position in Boston Scientific by 23.7% during the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after purchasing an additional 20,307 shares during the period. Finally, Beacon Investment Advisory Services Inc. boosted its position in Boston Scientific by 31.7% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock worth $1,744,000 after purchasing an additional 4,702 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the transaction, the director now directly owns 24,398 shares of the company's stock, valued at approximately $2,573,501.04. The trade was a 32.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. The trade was a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock worth $14,319,269 in the last three months. 0.50% of the stock is owned by insiders.

Remove Ads

Boston Scientific Trading Up 0.8 %

Shares of BSX traded up $0.83 during trading hours on Monday, hitting $100.19. The company had a trading volume of 2,738,831 shares, compared to its average volume of 7,015,744. The firm has a market cap of $148.18 billion, a P/E ratio of 80.21, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17. The stock's 50 day moving average price is $102.16 and its 200 day moving average price is $93.18. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Piper Sandler upped their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Truist Financial increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Friday, January 10th. Citigroup increased their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Finally, Argus set a $130.00 target price on Boston Scientific in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.